<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04902079</url>
  </required_header>
  <id_info>
    <org_study_id>CCM-001Mon</org_study_id>
    <nct_id>NCT04902079</nct_id>
  </id_info>
  <brief_title>Observational and Prospective Registry on Cardiac Contractility Modulation (CCM) Therapy</brief_title>
  <acronym>REPORT-CCM</acronym>
  <official_title>Observational and Prospective Registry on Cardiac Contractility Modulation (CCM) Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Monaldi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Monaldi Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational and perspective study with acute and chronic endpoint.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This registry includes patients who have undergone implantation of the cardiac contractility&#xD;
      modulation device due to the presence of heart failure with reduced left ventricular systolic&#xD;
      function and symptomatic despite optimal therapy, as indicated in the guidelines of the ESC&#xD;
      of 2016 and the Expert Consensus Document of the ESC Heart Failure group published in May&#xD;
      2019 for to assess the benefits after the CCM device.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement Quality of Life</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluatation of the impact on CCM Therapy on Quality of Life evaluated from the reduction of MLWHFQ score at FU post implant of CCM device compared to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Capacity</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of the impact on CCM Therapy on Functional Capacity evaluated from the gain of distance traveled in the 6MWT at FU post implant of CCM device compared to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of HF Hospitalizations and Emergency Ward accesses</measure>
    <time_frame>12 months</time_frame>
    <description>Reduction of HF Hospitalizations and Emergency Ward accesses at FU post implant of CCM device compared to number of HF hospitalization an Emergency Ward accesses collected 1 year before the implant of CCM therapy</description>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Heart Failure, Systolic</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Device for Cardiac Contractility Modulation Therapy (CCM)</intervention_name>
    <description>Evaluate the effect from CCM Therapy in HF population</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with standard indication to CardiaC Contractility Modulation (CCM) therapy device&#xD;
        system implantation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-pregnant female, aged 18 or older;&#xD;
&#xD;
          -  chronic heart failure with symptomatic left ventricular systolic function; (NYHA class&#xD;
             II-IVa) with or without device already implanted (for example AICD, pace-maker);&#xD;
&#xD;
          -  Appropriate and optimized medical therapy&#xD;
&#xD;
          -  Patient signed and dated informed consent form at enrollment;&#xD;
&#xD;
          -  life expectancy&gt; 1 year due to the absence of comorbidities that reduce the prognosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  absence of venous access available for implant;&#xD;
&#xD;
          -  contraindication to the interventional procedure of CCM device implant (for example&#xD;
             presence of Mechanical tricuspid vale);&#xD;
&#xD;
          -  pregnant patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio D'Onofrio, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ao dei Colli - Monaldi Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio D'Onofrio, MD</last_name>
    <phone>337768956</phone>
    <email>donofrionat1@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giuliano D'Alterio, MD</last_name>
    <phone>3332785271</phone>
    <email>gdalterio@libero.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Monaldi Hospital</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio D'Onofrio, MD</last_name>
      <email>donofrioant1@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 15, 2021</study_first_submitted>
  <study_first_submitted_qc>May 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2021</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Monaldi Hospital</investigator_affiliation>
    <investigator_full_name>Antonio D'Onofrio</investigator_full_name>
    <investigator_title>Head of UOSD Elettrofisiologia Studio e Terapia delle Aritmie</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Cardiac Contractility Modulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

